Hub : Traits :

Mood swings

547 significantly associated models · 76 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 205517299 205921859 1 1 1.9e-08 1.5e-06 7.8e-01 100 SLC41A1
2 3 48381826 51043528 14 2 1.4e-12 1.5e-10 1.2e-01 94 GPX1 RBM6
3 5 147516165 148067337 1 1 1.1e-07 5.4e-09 1.5e-02 83 FBXO38
4 7 11553163 12967449 1 1 1.5e-09 3.3e-09 1.2e-01 93 TMEM106B
5 8 8092025 11860845 9 1 6.8e-10 8.5e-10 1.4e-01 94 AF131215.2
6 8 140969818 142706843 1 1 4.4e-10 7.8e-09 7.1e-01 100 PTK2
7 9 119768572 121177842 1 1 8.1e-09 1.2e-08 1.0e+00 100 TLR4
8 11 46578400 48559571 8 1 2.8e-12 1.1e-11 2.0e-01 96 MADD
9 11 112542418 113969669 4 3 1.8e-09 4.0e-13 7.3e-04 78 ANKK1 DRD2 RP11-159N11.4
10 12 121453962 122915054 1 1 1.3e-07 5.4e-09 1.2e-02 81 TMEM120B
11 14 74531485 76089054 3 1 1.5e-08 1.6e-09 3.5e-02 88 DLST
12 16 86667409 89428967 3 2 1.0e-08 1.4e-08 1.0e+00 100 FBXO31 MVD
13 17 42607368 45796313 20 1 2.6e-17 4.2e-15 5.7e-01 100 WNT3
14 18 49172179 51753106 1 1 1.5e-07 8.7e-12 3.1e-06 53 DCC
15 18 52209411 54028036 1 1 1.0e-13 1.4e-13 8.0e-02 94 TCF4
16 22 40472399 42614362 7 1 3.0e-11 2.5e-12 2.0e-02 89 SLC25A17

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 2.74 2 1 2.2 0.00 1.0e+00 DCC SLC25A17
Depressed Affect (Nagel 2018) 16.81 17 13 28.9 0.99 8.2e-14 ANKK1 DCC DLST DRD2 FBXO31 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC41A1 TCF4 TLR4 TMEM106B TMEM120B WNT3
Depression (Nagel 2018) 7.39 6 1 2.2 0.98 3.9e-04 ANKK1 DCC MADD RP11-159N11.4 TMEM106B WNT3
Intelligence (Savage-Jansen 2018) 4.37 4 3 6.7 -0.97 3.1e-02 FBXO31 GPX1 RBM6 WNT3
Neuroticism (Nagel 2018) 16.46 17 12 26.7 0.97 6.2e-11 ANKK1 DCC DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 TCF4 TLR4 TMEM106B WNT3
Schizophrenia (2018) 2.83 2 0 0.0 0.00 1.0e+00 DCC SLC25A17
Worry (Nagel 2018) 10.17 10 6 13.3 1.00 1.3e-09 ANKK1 DLST DRD2 FBXO31 FBXO38 MADD RP11-159N11.4 SLC25A17 TMEM106B WNT3
Alzheimer’s Disease (including proxy) 2.24 1 0 0.0 0.00 1.0e+00 MADD
Crohns Disease (2017) 1.77 1 1 2.2 0.00 1.0e+00 GPX1
Irritable Bowel Disease (IBD) 2.42 2 1 2.2 0.00 1.0e+00 GPX1 RBM6
Ulcerative Colitis (UC) 2.34 2 1 2.2 0.00 1.0e+00 GPX1 RBM6
Major Depression (MDD) 5.18 3 0 0.0 0.00 1.0e+00 GPX1 TCF4 TMEM106B
Reaction Time 1.98 1 0 0.0 0.00 1.0e+00 FBXO31
Verbal and Numeric Reasoning (VNR) 3.66 3 2 4.4 0.00 1.0e+00 FBXO31 GPX1 RBM6
Breast Cancer 1.85 1 1 2.2 0.00 1.0e+00 WNT3
Ovarian Cancer 2.46 1 1 2.2 0.00 1.0e+00 WNT3
Prostate Cancer 3.11 2 0 0.0 0.00 1.0e+00 GPX1 SLC41A1
Age at First Birth 4.19 2 2 4.4 0.00 1.0e+00 GPX1 RBM6
Body Mass Index (BMI) (2010) 2.56 1 0 0.0 0.00 1.0e+00 MADD
Mean Putamen Volume 2.29 1 0 0.0 0.00 1.0e+00 WNT3
Fasting Glucose 2.80 1 1 2.2 0.00 1.0e+00 MADD
Lupus 1.64 1 0 0.0 0.00 1.0e+00 AF131215.2
Neuroticism (2016) 9.90 8 2 4.4 0.98 1.9e-05 AF131215.2 DRD2 GPX1 MADD SLC25A17 TCF4 TLR4 WNT3
Primary Biliary Cirrhosis 1.51 1 0 0.0 0.00 1.0e+00 WNT3
Schizophrenia (2014) 2.85 3 0 0.0 0.00 1.0e+00 DRD2 SLC25A17 WNT3
Ulcerative Colitis 2.03 1 1 2.2 0.00 1.0e+00 GPX1
Blood Eosinophil Count 1.59 5 3 6.7 0.10 8.7e-01 FBXO38 GPX1 RBM6 SLC25A17 WNT3
Blood Platelet Count 1.59 5 3 6.7 0.48 4.1e-01 DLST MADD PTK2 TMEM120B WNT3
Blood Red Count 3.03 3 2 4.4 0.00 1.0e+00 DRD2 MVD WNT3
Blood White Count 1.41 5 3 6.7 0.41 4.9e-01 FBXO38 GPX1 MADD RBM6 WNT3
Heel T-Score 1.42 6 2 4.4 -0.26 6.2e-01 DLST MADD RBM6 SLC25A17 TMEM120B WNT3
BMI 3.86 7 3 6.7 0.52 2.3e-01 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TLR4 TMEM120B
Height 1.55 9 9 20.0 -0.29 4.5e-01 DCC GPX1 MADD MVD SLC41A1 TCF4 TMEM106B TMEM120B WNT3
Waist Hip Ratio (WHR) 2.17 4 2 4.4 0.15 8.5e-01 GPX1 PTK2 RP11-159N11.4 WNT3
Systolic Blood Pressure 2.39 4 2 4.4 0.81 1.9e-01 FBXO38 GPX1 MADD PTK2
Smoking Status 3.38 4 1 2.2 -0.78 2.2e-01 FBXO31 GPX1 TMEM120B WNT3
Allergy or Eczema 1.26 1 1 2.2 0.00 1.0e+00 SLC25A17
Cardiovascular Disease 2.24 2 0 0.0 0.00 1.0e+00 DRD2 RP11-159N11.4
Respiratory disease 2.19 2 0 0.0 0.00 1.0e+00 MVD RBM6
Type 2 Diabetes (T2D) (2018) 2.16 1 0 0.0 0.00 1.0e+00 RBM6
Lung FEV1/FVC ratio 5.37 4 2 4.4 -0.80 2.0e-01 DLST FBXO38 PTK2 SLC41A1
Lung FVC 4.29 7 3 6.7 -0.75 5.2e-02 DCC FBXO38 GPX1 MVD RBM6 TCF4 WNT3
Neuroticism 16.53 17 14 31.1 0.98 1.7e-11 ANKK1 DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 SLC41A1 TCF4 TLR4 TMEM106B WNT3
Chronotype (morning person) 1.61 1 0 0.0 0.00 1.0e+00 RP11-159N11.4
Hair Pigment 0.46 5 2 4.4 0.61 2.7e-01 FBXO31 MVD SLC25A17 SLC41A1 WNT3
Tanning 0.45 1 0 0.0 0.00 1.0e+00 MVD
Hand grip strength (left) 3.51 4 4 8.9 -0.66 3.4e-01 MADD SLC41A1 TCF4 WNT3
Number of treatments/medications taken 4.67 3 2 4.4 0.00 1.0e+00 DLST GPX1 RBM6
Sensitivity / hurt feelings 8.73 7 4 8.9 0.99 3.4e-05 AF131215.2 ANKK1 DRD2 FBXO31 PTK2 RP11-159N11.4 WNT3
Frequency of depressed mood in last 2 weeks 8.43 6 0 0.0 0.99 7.0e-05 AF131215.2 ANKK1 DRD2 MADD TMEM106B WNT3
Hearing difficulty/problems: Yes 1.67 1 0 0.0 0.00 1.0e+00 PTK2
Relative age of first facial hair 4.10 2 1 2.2 0.00 1.0e+00 RBM6 WNT3
Systolic blood pressure, automated reading 2.80 4 3 6.7 0.59 4.1e-01 AF131215.2 FBXO38 GPX1 MADD
Medication: Co-codamol 2.23 1 0 0.0 0.00 1.0e+00 RBM6
Pack years adult smoking proportion 2.58 1 0 0.0 0.00 1.0e+00 GPX1
Impedance of leg (right) 2.72 5 4 8.9 -0.10 8.8e-01 AF131215.2 GPX1 MADD RBM6 SLC41A1
Leg fat-free mass (left) 2.10 5 3 6.7 0.21 7.4e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Trunk fat percentage 3.64 8 3 6.7 0.02 9.6e-01 ANKK1 FBXO31 GPX1 MADD RBM6 SLC25A17 TMEM120B WNT3
Hand grip strength (right) 2.96 4 3 6.7 -0.61 3.9e-01 MADD SLC41A1 TCF4 WNT3
Current tobacco smoking 3.28 1 0 0.0 0.00 1.0e+00 SLC25A17
Fed-up feelings 11.14 12 7 15.6 0.99 5.7e-09 AF131215.2 DCC DLST DRD2 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 TLR4 WNT3
Frequency of unenthusiasm / disinterest in last 2 weeks 7.20 5 0 0.0 0.97 5.7e-03 ANKK1 DCC DRD2 GPX1 RP11-159N11.4
Relative age voice broke 2.20 1 1 2.2 0.00 1.0e+00 WNT3
Taking other prescription medications 5.69 4 1 2.2 0.99 6.4e-03 DLST GPX1 RBM6 TMEM120B
Age when periods started (menarche) 3.45 3 2 4.4 0.00 1.0e+00 GPX1 MADD SLC41A1
Heel bone mineral density (BMD) T-score, automated (left) 2.94 1 1 2.2 0.00 1.0e+00 AF131215.2
Qualifications: CSEs or equivalent 2.06 1 0 0.0 0.00 1.0e+00 WNT3
High blood pressure 2.66 2 2 4.4 0.00 1.0e+00 AF131215.2 MADD
Sitting height 2.77 5 5 11.1 -0.37 5.4e-01 DCC FBXO31 MADD SLC41A1 WNT3
Body mass index (BMI) 4.65 5 4 8.9 0.30 6.2e-01 AF131215.2 GPX1 MADD RBM6 TMEM120B
Impedance of leg (left) 2.70 6 3 6.7 -0.13 8.1e-01 AF131215.2 GPX1 MADD RBM6 SLC41A1 WNT3
Leg predicted mass (left) 2.11 5 3 6.7 0.21 7.4e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Trunk fat mass 3.64 7 4 8.9 0.20 6.6e-01 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B WNT3
Waist circumference 3.33 5 3 6.7 0.55 3.4e-01 ANKK1 MADD RBM6 RP11-159N11.4 TMEM120B
Number of incorrect matches in round 2.64 1 0 0.0 0.00 1.0e+00 SLC41A1
Past tobacco smoking 2.03 1 0 0.0 0.00 1.0e+00 WNT3
Nervous feelings 8.16 7 3 6.7 0.98 1.0e-04 AF131215.2 ANKK1 DLST FBXO38 MADD SLC25A17 WNT3
Frequency of tenseness / restlessness in last 2 weeks 8.01 7 1 2.2 1.00 2.4e-06 ANKK1 DRD2 GPX1 MADD RBM6 TMEM106B WNT3
Hearing difficulty/problems with background noise 3.30 2 0 0.0 0.00 1.0e+00 SLC41A1 WNT3
Hair/balding pattern: Pattern 2 2.72 1 1 2.2 0.00 1.0e+00 WNT3
Forced vital capacity (FVC) 3.66 2 2 4.4 0.00 1.0e+00 GPX1 WNT3
Heel bone mineral density (BMD) T-score, automated (right) 3.00 1 1 2.2 0.00 1.0e+00 AF131215.2
Ever unenthusiastic/disinterested for a whole week 4.09 2 0 0.0 0.00 1.0e+00 RBM6 WNT3
Qualifications: None of the above 3.87 3 2 4.4 0.00 1.0e+00 GPX1 RBM6 TMEM120B
Financial difficulties in last 2 years 4.03 2 0 0.0 0.00 1.0e+00 DRD2 TMEM106B
Mouth/teeth dental problems 2.42 1 0 0.0 0.00 1.0e+00 WNT3
Diabetes (self-reported) 2.00 1 0 0.0 0.00 1.0e+00 RBM6
Fluid intelligence score 3.50 4 1 2.2 -0.51 4.9e-01 GPX1 MADD RBM6 TMEM120B
Neuroticism score 18.40 19 13 28.9 0.98 1.2e-12 AF131215.2 ANKK1 DCC DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 SLC41A1 TCF4 TLR4 TMEM106B WNT3
Weight 3.04 7 3 6.7 0.41 3.7e-01 AF131215.2 ANKK1 GPX1 MADD RBM6 SLC41A1 TMEM120B
Impedance of arm (right) 4.10 6 4 8.9 -0.45 3.7e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM106B WNT3
Arm fat percentage (right) 3.94 7 3 6.7 0.33 4.7e-01 AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Trunk fat-free mass 1.58 3 2 4.4 0.00 1.0e+00 AF131215.2 RBM6 SLC41A1
Hip circumference 2.88 5 3 6.7 0.34 5.7e-01 AF131215.2 GPX1 MADD RBM6 TMEM120B
Time employed in main current job 2.49 1 1 2.2 0.00 1.0e+00 WNT3
Alcohol intake versus 10 years previously 2.60 1 0 0.0 0.00 1.0e+00 RBM6
Father's age at death 2.50 1 0 0.0 0.00 1.0e+00 GPX1
Worrier / anxious feelings 9.43 6 5 11.1 0.95 3.3e-03 AF131215.2 DLST SLC25A17 TCF4 TLR4 WNT3
Frequency of tiredness / lethargy in last 2 weeks 6.00 4 0 0.0 0.86 1.4e-01 DCC GPX1 PTK2 TMEM106B
Hair/balding pattern: Pattern 3 5.01 1 1 2.2 0.00 1.0e+00 WNT3
Number of live births 1.90 2 0 0.0 0.00 1.0e+00 RBM6 WNT3
Forced expiratory volume in 1-second (FEV1) 5.12 3 3 6.7 0.00 1.0e+00 FBXO38 GPX1 WNT3
Qualifications: A levels/AS levels or equivalent 4.43 3 2 4.4 0.00 1.0e+00 GPX1 RBM6 TMEM120B
Mouth/teeth dental problems: Dentures 2.30 2 0 0.0 0.00 1.0e+00 GPX1 RBM6
Asthma 2.20 2 0 0.0 0.00 1.0e+00 MVD RBM6
Depression (self-reported) 3.93 1 0 0.0 0.00 1.0e+00 TMEM106B
Forced expiratory volume in 1-second (FEV1), Best measure 5.31 4 3 6.7 -0.94 6.4e-02 FBXO38 GPX1 MVD WNT3
Impedance of arm (left) 4.04 5 4 8.9 -0.53 3.6e-01 AF131215.2 GPX1 RBM6 TMEM106B WNT3
Arm fat mass (right) 4.11 7 4 8.9 0.39 3.8e-01 AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Trunk predicted mass 1.58 3 2 4.4 0.00 1.0e+00 AF131215.2 RBM6 SLC41A1
Standing height 1.67 5 4 8.9 -0.58 3.1e-01 GPX1 MADD SLC41A1 TMEM106B WNT3
Exposure to tobacco smoke at home 2.07 1 0 0.0 0.00 1.0e+00 RBM6
Tense / 'highly strung' 7.76 6 2 4.4 0.99 1.8e-04 AF131215.2 ANKK1 DRD2 RP11-159N11.4 SLC25A17 TMEM106B
Seen doctor (GP) for nerves, anxiety, tension or depression 7.34 5 3 6.7 0.98 3.6e-03 ANKK1 DRD2 GPX1 TCF4 TMEM106B
Hair/balding pattern: Pattern 4 5.96 1 1 2.2 0.00 1.0e+00 WNT3
Peak expiratory flow (PEF) 4.50 4 3 6.7 -0.69 3.1e-01 AF131215.2 FBXO38 SLC41A1 WNT3
Ever highly irritable/argumentative for 2 days 4.35 1 1 2.2 0.00 1.0e+00 RBM6
Qualifications: O levels/GCSEs or equivalent 2.42 1 1 2.2 0.00 1.0e+00 GPX1
Medication: Paracetamol 4.11 2 2 4.4 0.00 1.0e+00 GPX1 WNT3
Headache pain in last month 4.35 2 1 2.2 0.00 1.0e+00 TLR4 WNT3
Hypothyroidism/myxoedema (self-reported) 2.02 1 0 0.0 0.00 1.0e+00 AF131215.2
Birth weight 1.47 1 0 0.0 0.00 1.0e+00 SLC41A1
Chronic bronchitis/emphysema (mother) 2.66 1 0 0.0 0.00 1.0e+00 RBM6
High blood pressure (siblings) 1.80 1 0 0.0 0.00 1.0e+00 TMEM106B
Forced vital capacity (FVC), Best measure 3.93 3 2 4.4 0.00 1.0e+00 FBXO38 GPX1 WNT3
Body fat percentage 3.74 7 3 6.7 0.21 6.6e-01 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B WNT3
Leg fat percentage (right) 3.98 4 3 6.7 0.54 4.6e-01 ANKK1 GPX1 MADD RBM6
Arm fat-free mass (right) 2.22 5 3 6.7 0.27 6.6e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Exposure to tobacco smoke outside home 2.52 1 0 0.0 0.00 1.0e+00 RBM6
Comparative body size at age 10 3.51 3 2 4.4 0.00 1.0e+00 AF131215.2 MADD SLC41A1
Number of full brothers 3.27 1 0 0.0 0.00 1.0e+00 WNT3
Worry too long after embarrassment 6.10 5 2 4.4 0.97 6.6e-03 AF131215.2 ANKK1 DRD2 RP11-159N11.4 WNT3
Seen a psychiatrist for nerves, anxiety, tension or depression 5.21 1 0 0.0 0.00 1.0e+00 TMEM106B
Wheeze or whistling in the chest in last year 4.31 3 1 2.2 0.00 1.0e+00 GPX1 MVD RBM6
Age at first live birth 4.37 2 2 4.4 0.00 1.0e+00 GPX1 RBM6
Health satisfaction 4.19 2 0 0.0 0.00 1.0e+00 DRD2 GPX1
Qualifications: College or University degree 5.33 4 3 6.7 -0.96 3.7e-02 FBXO31 GPX1 RBM6 WNT3
Emphysema/chronic bronchitis 3.16 1 0 0.0 0.00 1.0e+00 WNT3
Medication for pain relief, constipation, heartburn 3.54 3 1 2.2 0.00 1.0e+00 DLST GPX1 WNT3
Neck or shoulder pain in last month 2.65 2 0 0.0 0.00 1.0e+00 GPX1 PTK2
Medication: Seretide 50 evohaler 2.01 1 0 0.0 0.00 1.0e+00 RBM6
Mean time to correctly identify matches 2.24 2 0 0.0 0.00 1.0e+00 FBXO31 SLC41A1
Whole body fat mass 3.98 6 4 8.9 0.55 2.6e-01 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Leg fat mass (right) 4.34 7 3 6.7 0.47 2.9e-01 AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Arm predicted mass (right) 2.26 5 3 6.7 0.25 6.8e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Alcohol intake frequency. 4.89 7 3 6.7 0.29 5.3e-01 DCC DRD2 MADD RBM6 RP11-159N11.4 TCF4 WNT3
Comparative height size at age 10 2.36 5 4 8.9 -0.59 3.0e-01 DLST GPX1 SLC41A1 TCF4 WNT3
Suffer from 'nerves' 8.30 6 3 6.7 0.97 1.2e-03 AF131215.2 ANKK1 DLST DRD2 MADD WNT3
Overall health rating 6.61 7 3 6.7 0.98 1.6e-04 ANKK1 FBXO38 GPX1 PTK2 RBM6 RP11-159N11.4 TMEM120B
Chest pain or discomfort 2.63 1 0 0.0 0.00 1.0e+00 GPX1
Age at last live birth 4.56 2 2 4.4 0.00 1.0e+00 GPX1 RBM6
Leg pain on walking 2.68 1 0 0.0 0.00 1.0e+00 WNT3
Supplements: Vitamin C 1.59 1 0 0.0 0.00 1.0e+00 WNT3
Hypertension (Self-reported) 2.49 2 1 2.2 0.00 1.0e+00 AF131215.2 MADD
Illnesses of father: Heart disease 1.57 1 0 0.0 0.00 1.0e+00 WNT3
Whole body fat-free mass 1.82 5 3 6.7 0.21 7.4e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg fat-free mass (right) 2.09 4 3 6.7 0.18 8.2e-01 AF131215.2 RBM6 SLC41A1 TMEM120B
Arm fat percentage (left) 4.03 6 3 6.7 0.28 5.8e-01 AF131215.2 ANKK1 GPX1 MADD RBM6 TMEM120B
Average weekly red wine intake 2.30 1 0 0.0 0.00 1.0e+00 RBM6
Handedness (chirality/laterality): Left-handed 2.76 1 1 2.2 0.00 1.0e+00 WNT3
Loneliness, isolation 7.25 5 2 4.4 0.98 2.9e-03 GPX1 MADD RP11-159N11.4 TMEM106B WNT3
Diabetes diagnosed by doctor 2.31 1 0 0.0 0.00 1.0e+00 RBM6
Mouth/teeth dental problems: Mouth ulcers 2.60 1 1 2.2 0.00 1.0e+00 WNT3
Back pain experienced in last month 2.58 1 0 0.0 0.00 1.0e+00 PTK2
Asthma (self-reported) 2.28 2 0 0.0 0.00 1.0e+00 MVD RBM6
Forced expiratory volume in 1-second (FEV1), predicted percentage 4.10 2 2 4.4 0.00 1.0e+00 FBXO38 WNT3
Whole body water mass 1.85 5 3 6.7 0.21 7.3e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg predicted mass (right) 2.06 4 3 6.7 0.18 8.2e-01 AF131215.2 RBM6 SLC41A1 TMEM120B
Arm fat mass (left) 4.13 7 4 8.9 0.38 4.0e-01 AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Number of self-reported non-cancer illnesses 3.87 1 0 0.0 0.00 1.0e+00 TMEM106B
Average weekly champagne plus white wine intake 2.46 1 0 0.0 0.00 1.0e+00 WNT3
Miserableness 13.84 10 8 17.8 0.98 6.8e-07 AF131215.2 ANKK1 DRD2 GPX1 MADD RBM6 RP11-159N11.4 TCF4 TMEM106B WNT3
Guilty feelings 9.60 7 4 8.9 0.98 1.4e-04 AF131215.2 ANKK1 DLST DRD2 MADD RP11-159N11.4 WNT3
Financial situation satisfaction 4.48 1 1 2.2 0.00 1.0e+00 GPX1
Medication: Blood pressure 1.75 1 0 0.0 0.00 1.0e+00 AF131215.2
Medication: Bendroflumethiazide 2.35 2 0 0.0 0.00 1.0e+00 AF131215.2 MADD
Medication: Paracetamol 4.11 2 1 2.2 0.00 1.0e+00 GPX1 WNT3
Illnesses of father: High blood pressure 1.68 1 0 0.0 0.00 1.0e+00 MADD
Basal metabolic rate 2.10 5 3 6.7 0.27 6.6e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg fat percentage (left) 4.21 5 3 6.7 0.56 3.2e-01 ANKK1 GPX1 MADD RBM6 TMEM120B
Arm fat-free mass (left) 2.33 5 3 6.7 0.32 6.0e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Number of operations (self-reported) 3.50 2 0 0.0 0.00 1.0e+00 GPX1 RBM6
Average weekly beer plus cider intake 3.47 2 1 2.2 0.00 1.0e+00 AF131215.2 RBM6
Irritability 10.31 10 4 8.9 0.97 2.2e-06 AF131215.2 ANKK1 DRD2 GPX1 MVD SLC25A17 TCF4 TLR4 TMEM106B WNT3
Risk taking 1.89 1 0 0.0 0.00 1.0e+00 AF131215.2
Fractured/broken bones in last 5 years 1.55 1 0 0.0 0.00 1.0e+00 WNT3
Diastolic blood pressure, automated reading 2.24 4 1 2.2 0.49 5.1e-01 AF131215.2 GPX1 MADD RBM6
Ever depressed for a whole week 3.91 1 0 0.0 0.00 1.0e+00 RBM6
Vascular/heart problems diagnosed by doctor 2.50 2 1 2.2 0.00 1.0e+00 AF131215.2 MADD
Pain experienced in last month 3.96 4 1 2.2 -0.97 2.9e-02 GPX1 MVD PTK2 WNT3
Pack years of smoking 2.52 1 0 0.0 0.00 1.0e+00 GPX1
Impedance of whole body 3.60 5 4 8.9 -0.42 4.8e-01 AF131215.2 GPX1 RBM6 SLC41A1 WNT3
Leg fat mass (left) 4.55 7 5 11.1 0.46 2.9e-01 AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Arm predicted mass (left) 2.36 5 4 8.9 0.29 6.4e-01 AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 12 0.344 1.8
GTEx Adipose Visceral Omentum 11 0.540 2.0
GTEx Adrenal Gland 8 0.549 1.9
GTEx Artery Aorta 12 0.403 2.0
GTEx Artery Coronary 10 0.845 2.1
GTEx Artery Tibial 8 0.213 1.8
GTEx Brain Caudate basal ganglia 7 0.761 2.0
GTEx Brain Cerebellar Hemisphere 10 0.672 1.9
GTEx Brain Cerebellum 12 0.605 1.9
GTEx Brain Cortex 10 0.966 2.1
GTEx Brain Frontal Cortex BA9 6 0.649 2.0
GTEx Brain Hippocampus 4 0.763 2.1
GTEx Brain Hypothalamus 5 0.847 2.1
GTEx Brain Nucleus accumbens basal ganglia 7 0.809 2.0
GTEx Brain Putamen basal ganglia 4 0.641 2.1
GTEx Breast Mammary Tissue 9 0.456 1.9
GTEx Breast Mammary Tissue (Male) 7 0.587 2.0
GTEx Breast Mammary Tissue (Female) 9 0.547 2.0
GTEx Cells EBV-transformed lymphocytes 12 0.843 2.1
GTEx Cells Transformed fibroblasts 11 0.262 1.8
GTEx Colon Sigmoid 10 0.684 2.0
GTEx Colon Transverse 10 0.484 1.9
GTEx Esophagus Gastroesophageal Junction 10 0.692 2.0
GTEx Esophagus Mucosa 16 0.482 1.9
GTEx Esophagus Muscularis 17 0.526 2.0
GTEx Heart Atrial Appendage 8 0.507 1.9
GTEx Heart Left Ventricle 9 0.588 2.0
GTEx Liver 4 0.558 2.0
GTEx Lung 13 0.452 1.9
GTEx Muscle Skeletal 10 0.346 1.8
GTEx Nerve Tibial 12 0.278 1.8
GTEx Ovary 7 0.771 2.2
GTEx Pancreas 9 0.551 1.9
GTEx Pituitary 6 0.538 2.0
GTEx Prostate 7 0.838 2.0
GTEx Skin Not Sun Exposed Suprapubic 12 0.488 2.0
GTEx Skin Sun Exposed Lower leg 15 0.412 1.9
GTEx Small Intestine Terminal Ileum 4 0.868 2.2
GTEx Spleen 9 0.638 2.0
GTEx Stomach 9 0.619 2.0
GTEx Testis 11 0.349 1.9
GTEx Thyroid 16 0.400 1.8
GTEx Uterus 8 1.411 2.4
GTEx Vagina 6 0.945 2.0
GTEx Whole Blood 6 0.301 1.8
METSIM Adipose 4 0.087 1.7
NTR Blood 8 0.333 1.7
ROSMAP Brain Pre-frontal Cortex 5 0.114 1.7
YFS Blood 7 0.152 1.6
CommonMind Brain Pre-frontal Cortex 6 0.112 1.7
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.7
The Cancer Genome Atlas Breast Invasive Carcinoma 5 0.113 1.6
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.273 1.8
The Cancer Genome Atlas Colon Adenocarcinoma 4 0.194 1.8
The Cancer Genome Atlas Esophageal Carcinoma 3 0.438 2.0
The Cancer Genome Atlas Glioblastoma Multiforme 4 0.391 1.8
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 7 0.257 1.8
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 6 0.146 1.6
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 3 0.146 1.8
The Cancer Genome Atlas Brain Lower Grade Glioma 4 0.093 1.6
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.181 1.7
The Cancer Genome Atlas Lung Adenocarcinoma 8 0.272 1.7
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 6 0.239 1.7
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 5 0.314 1.8
The Cancer Genome Atlas Pancreatic Adenocarcinoma 3 0.181 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 3 0.226 1.8
The Cancer Genome Atlas Prostate Adenocarcinoma 8 0.173 1.6
The Cancer Genome Atlas Rectum Adenocarcinoma 2 0.289 1.7
The Cancer Genome Atlas Soft Tissue Sarcoma 3 0.281 1.7
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.6
The Cancer Genome Atlas Stomach Adenocarcinoma 5 0.297 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 4 0.313 1.7
The Cancer Genome Atlas Thyroid Carcinoma 6 0.116 1.6
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.394 1.8